AAAAAA

   
Results: 1-8 |
Results: 8
Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer
Authors: Tuxen, MK Soletormos, G Petersen, PH Dombernowsky, P
Citation: Mk. Tuxen et al., Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer, CLIN CH L M, 39(6), 2001, pp. 531-538
Tumor marker CA125 in ovarian cancer
Authors: Tuxen, MK
Citation: Mk. Tuxen, Tumor marker CA125 in ovarian cancer, J TUMOR M, 16(1), 2001, pp. 49-68
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
Authors: Tuxen, MK Soletormos, G Dombernowsky, P
Citation: Mk. Tuxen et al., Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy, BR J CANC, 84(10), 2001, pp. 1301-1307
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
Authors: Neijt, JP Engelholm, SA Tuxen, MK Sorensen, PG Hansen, M Sessa, C de Swart, CAM Hirsch, FR Lund, B van Houwelingen, HC
Citation: Jp. Neijt et al., Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer, J CL ONCOL, 18(17), 2000, pp. 3084-3092
Biological variation and analytical imprecision of CA 125 in patients withovarian cancer
Authors: Tuxen, MK Soletormos, G Rustin, GJS Nelstrop, AE Dombernowsky, P
Citation: Mk. Tuxen et al., Biological variation and analytical imprecision of CA 125 in patients withovarian cancer, SC J CL INV, 60(8), 2000, pp. 713-721
Gemcitabine in the treatment of ovarian cancer
Authors: Hansen, SW Tuxen, MK Sessa, C
Citation: Sw. Hansen et al., Gemcitabine in the treatment of ovarian cancer, ANN ONCOL, 10, 1999, pp. 51-53
Advanced epithelial ovarian cancer: 1998 consensus statements
Authors: Berek, JS Bertelsen, K du Bois, A Brady, MF Carmichael, J Eisenhauer, EA Gore, M Grenman, S Hamilton, TC Hansen, SW Harper, PG Horvath, G Kaye, SB Luck, HJ Lund, B McGuire, WP Neijt, JP Ozols, RF Parmar, MKB Piccart-Gebhart, MJ van Rijswijk, R Rosenberg, P Rustin, GJS Sessa, C Thigpen, JT Trope, C Tuxen, MK Vergote, I Vermorken, JB Willemse, PHB
Citation: Js. Berek et al., Advanced epithelial ovarian cancer: 1998 consensus statements, ANN ONCOL, 10, 1999, pp. 87-92
Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer
Authors: Tuxen, MK Soletormos, G Petersen, PH Schioler, V Dombernowsky, P
Citation: Mk. Tuxen et al., Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer, GYNECOL ONC, 74(1), 1999, pp. 12-22
Risultati: 1-8 |